At Pfizer, we have a deep industry-leading commitment to understanding the origins of brain disorders and to developing innovative medicines that effectively treat Alzheimer’s disease, autism, bipolar disorder, depression, Parkinson’s disease, schizophrenia, among others.

Breakthroughs that change patient’s lives

The pursuit of delivering breakthroughs is basic to Pfizer’s culture. It shapes our strategy, defines our purpose, and governs every facet of our operations — from research and development (R&D) that leads to pharmaceutical inventions, to the transfer of knowledge to patients and providers, to the way we respond to the changing marketplace.

Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. And today we’re taking on some of the world’s most difficult diseases, including cancer, arthritis, and osteoporosis.

Pfizer Limited

Pfizer Limited was listed on the Indian stock exchange in 1966. Today, the company has over one lac shareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 15 therapeutic areas.

Its top brands include Prevenar 13, Lyrica, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa that produces more than a billion tablets annually.

The Company employs 2,631 colleagues, and is committed to providing therapies to prevent and treat some of the most critical diseases that impact public health in India today.